Reproductive Endocrinology Neuroendocrinology

Progesterone - Friend or foe?

Sundström-Poromaa I, Comasco E, Sumner R, Luders E

Published October 2020 Frontiers in Neuroendocrinology, 59, 100856
DOI 10.1016/j.yfrne.2020.100856 PMID 32730861

RRM Academy Synopsis

Progesterone can help and harm mood in different women

A 2020 narrative review of human and animal research finds that a progesterone byproduct helps treat postpartum depression but may worsen premenstrual dysphoric disorder. The byproduct is allopregnanolone. The authors say knowledge of its benefits and harms is still limited.

Key Findings

  • In women of childbearing age, 18% have at least one mood symptom in the luteal phase, and 2–5% meet criteria for PMDD.
  • Women with PMDD show progesterone and allopregnanolone levels similar to healthy women. Their worst symptoms arrive late in the luteal phase, as levels fall.
  • Three placebo-controlled randomized trials of hormonal contraception in healthy women exist. All three found small but significant shifts toward worse mood.
  • Large register studies put the risk of needing antidepressant treatment for contraceptive mood side effects at 0.9 out of 100 users. Surveys suggest around 4–10% have mood symptoms.
  • Brexanolone, in the authors' words allopregnanolone, was tested in three randomized controlled trials for postpartum depression. It acted rapidly, with results sustained over 30 days.

Interpretation

The paper is a narrative review by four researchers. The authors explain the opposite mood effects through individual sensitivity to hormone change, since women with PMDD have similar hormone levels to healthy women. They call for risk markers for progesterone sensitivity, and for studies that compare women with PMDD and women with postpartum depression.

RRM Context

Mood symptoms that follow the menstrual cycle point to the hormonal events of the cycle itself, and postpartum mood symptoms follow the hormonal shift after delivery. The review says the mechanism linking allopregnanolone to PMDD has not been established. It also says mood effects are a major reason women stop hormonal contraception. Restorative reproductive medicine treats the cycle as diagnostic information and looks for the cause of cyclic mood problems.

Abstract

Estradiol is the "prototypic" sex hormone of women. Yet, women have another sex hormone, which is often disregarded: Progesterone. The goal of this article is to provide a comprehensive review on progesterone, and its metabolite allopregnanolone, emphasizing three key areas: biological properties, main functions, and effects on mood in women. Recent years of intensive research on progesterone and allopregnanolone have paved the way for new treatment of postpartum depression. However, treatment for premenstrual syndrome and premenstrual dysphoric disorder as well as contraception that women can use without risking mental health problems are still needed. As far as progesterone is concerned, we might be dealing with a two-edged sword: while its metabolite allopregnanolone has been proven useful for treatment of PPD, it may trigger negative symptoms in women with PMS and PMDD. Overall, our current knowledge on the beneficial and harmful effects of progesterone is limited and further research is imperative.

Topics

By this author

Related research

Reproductive Endocrinology › Neuroendocrinology › Hypothalamic Pituitary Axis · Postpartum › Mental Health › Postpartum Depression · Therapeutics › Hormonal Agents › Progesterone and Progestins
Inger Sundström-Poromaa, Erika Comasco, Rachael Sumner, Eileen Luders
I Sundström-Poromaa, E Comasco, R Sumner, E Luders
PMID 32730861 32730861 DOI 10.1016/j.yfrne.2020.100856 10.1016/j.yfrne.2020.100856 Sundström-Poromaa et al. 2020, Sundström-Poromaa 2020